These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 9410069

  • 1. [Pharmacoeconomics of meropenem versus imipenem/cilastatin].
    Marquina MC, Giráldez J, Idoate A.
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():45-50. PubMed ID: 9410069
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections.
    Attanasio E, Russo P, Carunchio G, Basoli A, Caprino L.
    Dig Surg; 2000 Sep; 17(2):164-72. PubMed ID: 10781982
    [Abstract] [Full Text] [Related]

  • 3. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
    Dietrich ES, Schubert B, Ebner W, Daschner F.
    Pharmacoeconomics; 2001 Jan; 19(1):79-94. PubMed ID: 11252548
    [Abstract] [Full Text] [Related]

  • 4. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.
    Edwards SJ, Campbell HE, Plumb JM.
    Eur J Health Econ; 2006 Mar; 7(1):72-8. PubMed ID: 16429296
    [Abstract] [Full Text] [Related]

  • 5. Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients.
    Nelson WK, Rayback PA, Quinones R, Giller RH.
    Ann Pharmacother; 2002 Sep; 36(9):1360-5. PubMed ID: 12196052
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
    Arnold HM, McKinnon PS, Augustin KM, Hladnik LM, Casabar E, Reichley RM, Dubberke ER, Westervelt P, Ritchie DJ.
    Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
    Richerson MA, Ambrose PG, Quintiliani R, Nightingale CH.
    Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
    McKinnon PS, Paladino JA, Grayson ML, Gibbons GW, Karchmer AW.
    Clin Infect Dis; 1997 Jan; 24(1):57-63. PubMed ID: 8994756
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Carbapenems in serious infections: a risk-benefit assessment.
    Norrby SR.
    Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.